


PRT62607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures
Following Oral Dosing in Healthy Volunteers


Coffey et al

Supplemental Figure S1


A




B



C



D



Supplemental Figure S1: Relationship between Cmax, AUC, and Dose of PRT062607 following single and multiple oral administration of PRT062607. Mean (SD) PRT062607 dose-normalized Cmax (A and C) and dose-normalized AUC (B and D) are related to dose for the SAD (A and B) and MAD (C and D) studies.